Abstract
Hypoxia induces a cascade of physiological responses that includes glycolysis, erythropoiesis, angiogenesis, changes in adrenergic signal transduction and vascular cellular proliferation. Hypoxia-inducible genes are relevant to growth and behaviour of cancer as well as the adaptation and survival of normal tissues. Hypoxia-inducible factor-1 (HIF-1) is a heterodimeric DNA binding complex composed of two basic-helix-loop-helix PAS-proteins: HIF-1 beta/ARNT (aryl hydrocarbon receptor nuclear translocator), which is constitutively expressed, and HIF-1 alpha, which is not present in normoxic cells but induced under hypoxic conditions. Recently another member of the bHLH-PAS family, EPAS-1 has been reported and shares similar properties with HIF-1 alpha, although it is considered endothelial specific. In addition, the presence of other DNA-binding motifs in the promoter of hypoxia-inducible genes highlight the occurrence of cross-talk between transcription factors in the modulation of hypoxic gene expression. In this review, we present a survey of the hypoxia response pathway and we discuss attempts to use gene therapy activated by the low oxygen environment or by necrotic regions of tumours.
Similar content being viewed by others
References
Wenger RH, Gassman M: Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 378: 609-616, 1997
Wang GL, Jiang BH, Rue EA, Semenza GL: Hypoxia-inducible factor-1 is a basic-helix-loop-helix-pas heterodimer regulated by cellular O-2 tension. Proc Natl Acad Sci USA 92: 5510-5514, 1995
Reyes H, S. R-P, Hankinson O: Ah receptor nuclear translocator protein (ARNT) as a component of the DNA binding form of the Ah receptor. Science 256: 1193-1195, 1992
Hahn ME, Karchner SI, Shapiro MA, Perera SA: Molecular evolution of 2 vertebrate aryl-hydrocarbon (dioxin) receptors (ahr1 and ahr2) and the pas family. Proc Natl Acad Sci USA 94: 13743-13748, 1997
Schmidt JV, Bradfield CA: Ah receptor signalling pathways. Annu Rev Cell Dev Biol 12: 55-89, 1996
Zelzer E, Wappner P, Shilo BZ: The pas domain confers target gene specificity of drosophila bhlh/pas proteins. Genes Dev 11: 2079-2089, 1997
Jiang BJ, Semenza GL, Bauer C, Marti HH: Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 271: C1172-C1180, 1996
Semenza GL: Transcriptional regulation by hypoxia-inducible factor 1. Molecular mechanisms of oxygen homeostasis. Trends Cardiovasc Med 6: 151-157, 1996
Bunn HF, Poyton RO: Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 76: 839-885, 1996
Gleadle JM, Ebert BL, Ratcliffe PJ: Deiphenylene iodonium inhibits the induction of erythropoietin and other mammalian genes by hypoxia: Implications for the mechanism of oxygen sensing. Eur J Biochem 234: 92-99, 1995
Salccda S, Caro J: Hypoxia inducible factor 1 alpha (hif 1 alpha) protein is rapidly degraded by the ubiquitin-protea-some system under normoxic conditions — its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272: 22642-22647, 1997
Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L: Activation of hypoxia-inducible factor 1-alpha-posttranscriptional regulation and conformational change by recruitment of the arnt transcription factor. Proc Natl Acad Sci USA 94: 5667-5672, 1997
Tian H, McKnight SL, Russel DW: Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11: 72-82, 1997
Shikama N, Lyon J, La Thangue NB: The p300/CBP family: Integrating signals with transcription factors and chromatin. Trends in Cell Biology 7: 230-236, 1997
Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, Bunn HF, Livingston DM: An essential role for p300/cbp in the cellular-response to hypoxia. Proc Natl Acad Sci USA 93: 12969-12973, 1996
Firth JD, Ebert BL, Ratcliffe PJ: Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements. J Biol Chem 270: 21021-21027, 1995
Levy AP, Levy NS, Iliopoulos O, Jiang C, Kaelin WG, Goldberg MA: Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Kidney International 51: 575-578, 1997
Levy AP, Levy NS, Goldberg MA: Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J Biol Chem 271: 25492-25497, 1996
Damert A, Ikeda E, Risau W: Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth-factor expression in c6 glioma-cells. Biochem J 327: 419-423, 1997
Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ: Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth-factor expression. Cancer Res 56: 3436-3440, 1996
Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, Kerbel RS: Mutant ras oncogenes up-regulate vegf/vpf expression — implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-4580, 1995
Petit AMV, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS: Neutralizing antibodies against epidermal growth-factor and erbb-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth-factor production by tumor-cells in-vitro and in-vivo-angiogenic implications for signal-transduction therapy of solid tumours. Am J Pathol 151: 1523-1530, 1997
Griffiths L, Dachs GU, Bicknell R, Harris AL, Stratford IJ: The influence of oxygen-tension and pH on the expression of platelet-derived endothelial-cell growth-factor thymidine phosphorylase in human breast-tumor cells grown in-vitro and in-vivo. Cancer Res 57: 570-572, 1997
Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW, Rateliffe PJ: Hypoxia-inducible factor-1 modulates gene-expression in solid tumours and influences both angiogenesis and tumor-growth. Proc Natl Acad Sci USA 94: 8104-8109, 1997
Adams GE, Hasan NM, Joiner MC: Radiation, hypoxia and genetic stimulation-implications for future therapies. Radiother Oncol 44: 101-109, 1997
Wouters BG, Brown JM: Cells at intermediate oxygen levels can be more important than the hypoxic fraction in determining tumor response to fractionated radiotherapy. Radiat Res 147: 541-550, 1997
Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38: 285-289, 1997
Patterson AV, Saunders MP, Chinje EC, Talbot DC, Harris AL, Stratford IJ: Overexpression of human NADPH: cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 76: 1338-1347, 1997
Dachs GU, Patterson AV, Firth JD, Rateliffe PJ, Townsend KMS, Stratford IJ, Harris AL: Targeting gene-expression to hypoxic tumor-cells. Nature Med 3: 515-520, 1997
Teicher BA, Holden SA, Ara G, Sotomayor EA, Huang ZD, Chen YN, Brem H: Potentiation of cytotoxic cancer therapies by tnp-470 alone and with other anti-angiogenic agents. Int J Cancer 57: 920-925, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Blancher, C., Harris, A.L. The molecular basis of the hypoxia response pathway: Tumour hypoxia as a therapy target. Cancer Metastasis Rev 17, 187–194 (1998). https://doi.org/10.1023/A:1006002419244
Issue Date:
DOI: https://doi.org/10.1023/A:1006002419244